Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake.
Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future.
Although 2026 has been a good year for the S&P 500 and the stock market as a whole, now may be a time for investors to ...
The drugmaker maintained its quarterly payout at 43 cents a share, leaving investors with a forward yield of roughly 6.25%.
Pfizer Inc. (ISIN US7170811035) declared a USD 0.43 fourth-quarter dividend on October 6, 2026, with payment scheduled for ...
If you've been looking for high-yield stocks, Pfizer (PFE-1.40%) may have crossed your radar screen. As shares of the pharma ...
Pfizer Inc. ( PFE) announced that its Board of Directors has declared a fourth-quarter 2026 cash dividend of $0.43 per share on the company's common stock. The dividend will be paid on December 7, ...
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, to holders of the Common ...
Pfizer (PFE) currently faces dual concerns in the market about its growth prospects and dividend safety, causing its valuation to remain low. However, from the perspective of financial ...
Pfizer's (PFE) 6% yield looks attractive until you realize shares fell nearly 20% over five years to manufacture it. Pfizer paid out $9.77 billion in 2025 dividends, consuming nearly all free cash ...
Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the ...
Pfizer delivered a Q2 double beat, raised full-year revenue guidance, and benefits from pipeline progress. Read why PFE stock is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results